Trial Profile
A 52 week, Single center, Open-label Study to Evaluate Neutrophil function and survival effects of Tocilizumab (TCZ) in Patients with Active Rheumatoid Arthritis (RA) on Background Non-biologic DMARDs who have an Inadequate Response to Current Non-biologic DMARD and/or Anti-TNF Therapy.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Tocilizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- Sponsors Roche
- 06 Jul 2012 Actual end date (1 Dec 2011) added as reported by ClinicalTrials.gov.
- 16 Mar 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Dec 2011 Actual patient number is 19 according to ClinicalTrials.gov.